ResearcherCapital Medical UniversityActive in the last 2 years

Li Min

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9595-5536; OpenAlex author ID A5100750705. Sources: ClinicalTrials.gov.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 1 (principal investigator on 1)
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 trial

Papers 2

Trials 1

Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis Principal investigator NCT06363123 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Shutian Zhang · 2 shared papers, 2020–2021 · strength 0.29
- Paper Detection of Pancreatic Ductal Adenocarcinoma by A qPCR-based Normalizer-free Circulating Extracellular Vesicles RNA Si… DOI 10.7150/jca.50716 ↗
- Paper ECT2 Increases the stability of EGFR and Tumorigenicity by Inhibiting Grb2 Ubiquitination in Pancreatic Cancer. DOI 10.3389/fonc.2020.589241 ↗
Yu Zhao · 1 shared paper, 2021 · strength 0.16
- Paper Detection of Pancreatic Ductal Adenocarcinoma by A qPCR-based Normalizer-free Circulating Extracellular Vesicles RNA Si… DOI 10.7150/jca.50716 ↗
Da Qin · 1 shared paper, 2021 · strength 0.16
- Paper Detection of Pancreatic Ductal Adenocarcinoma by A qPCR-based Normalizer-free Circulating Extracellular Vesicles RNA Si… DOI 10.7150/jca.50716 ↗
Junxiong Wang · 1 shared paper, 2020 · strength 0.13
- Paper ECT2 Increases the stability of EGFR and Tumorigenicity by Inhibiting Grb2 Ubiquitination in Pancreatic Cancer. DOI 10.3389/fonc.2020.589241 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.